Edda Technology’s IQQA-BodyImaging Will Provide 3D Assessment in SIO’s ACCLAIM Trial

April 18, 2022—Edda Technology announced it has entered into an agreement with the Society of Interventional Oncology (SIO) for the ACCLAIM trial. The company’s IQQA-BodyImaging Interventional will be used to provide three-dimensional (3D) assessment of the ablation zone and margin for selected colorectal liver metastases.

According to the company, the IQQA platform provides comprehensive 3D image analysis using MR and CT to support in-depth quantitative volumetry with fast and dependable results and allows for versatility of transplantation, resection, or interventional procedure planning.

In this prospective, multicenter, international trial, SIO proposes to establish microwave ablation (MWA) as the preferred treatment option for selected colorectal liver metastases that can be ablated with sufficient margins.

As noted in the press release, the global prospective trial will use an objective and reproducible technical outcome in its study design, which SIO believes will drive important changes to future treatment guidelines. The ACCLAIM study will estimate disease-free survival of colorectal liver metastases treated with MWA incorporating Edda Technology’s 3D ablation software margin confirmation intraoperatively and through a subsequent independent review centralized validation process.